138 related articles for article (PubMed ID: 7538047)
1. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H; Giai M; Diamandis EP; Katsaros D; Sutherland DJ; Levesque MA; Roagna R; Ponzone R; Sismondi P
Cancer Res; 1995 May; 55(10):2104-10. PubMed ID: 7538047
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H; Levesque MA; Clark GM; Diamandis EP
Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
[TBL] [Abstract][Full Text] [Related]
3. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
4. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer.
Heyl W; Wolff JM; Biesterfeld S; Schröder W; Zitzelsberger D; Jakse G; Rath W
Anticancer Res; 1999; 19(4A):2563-5. PubMed ID: 10470195
[TBL] [Abstract][Full Text] [Related]
6. Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer.
Griniatsos J; Diamantis E; Gioti J; Karyda I; Vassilopoulos PP; Agnanti N
Anticancer Res; 1998; 18(1B):683-8. PubMed ID: 9584052
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen (PSA) in breast and ovarian cancer.
Kucera E; Kainz C; Tempfer C; Zeillinger R; Koelbl H; Sliutz G
Anticancer Res; 1997; 17(6D):4735-7. PubMed ID: 9494598
[TBL] [Abstract][Full Text] [Related]
8. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
9. [Determination of prostate-specific antigen (PSA) in cytosol of breast tumors and human endometrium--new diagnostic approaches].
Seliger E; Kaltwasser P; Röpke F
Zentralbl Gynakol; 1998; 120(4):172-5. PubMed ID: 9610520
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen value as a marker in breast cancer.
Narita D; Cimpean AM; Anghel A; Raica M
Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
12. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
13. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
Mulligan AM; O'Malley FP; Ennis M; Fantus IG; Goodwin PJ
Breast Cancer Res Treat; 2007 Nov; 106(1):39-47. PubMed ID: 17221153
[TBL] [Abstract][Full Text] [Related]
14. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.
Scorilas A; Diamandis EP; Levesque MA; Papanastasiou-Diamandi A; Khosravi MJ; Giai M; Ponzone R; Roagna R; Sismondi P; López-Otin C
Clin Cancer Res; 1999 Jul; 5(7):1778-85. PubMed ID: 10430082
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk.
Sauter ER; Daly M; Linahan K; Ehya H; Engstrom PF; Bonney G; Ross EA; Yu H; Diamandis E
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):967-70. PubMed ID: 8959318
[TBL] [Abstract][Full Text] [Related]
16. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Scorilas A; Borgoño CA; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
J Clin Oncol; 2004 Feb; 22(4):678-85. PubMed ID: 14966091
[TBL] [Abstract][Full Text] [Related]
17. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
[TBL] [Abstract][Full Text] [Related]
19. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
20. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]